ANIK

Anika is a small orthopedic/regenerative-medicine maker whose top line has gone nowhere-to-down for years: revenue fell from $148M (FY2021) to $113M (FY2025), a fifth straight year without durable growth and -5.9% in the latest year. Profitability is the crux of the debate. Headline net loss narrowed dramatically to -$10.9M (from -$56.4M in FY2024 and -$82.7M in FY2023, +80.7% YoY), and operating cash flow swung positive to $11.2M — real improvement. But the underlying operating picture still deteriorated: gross profit dropped 16.0% and gross margin compressed to 56.6%, and operating income fell to -$11.1M (-116.6% YoY). So the loss narrowing is more about the absence of prior-year impairments than a return to profitable core operations.

The balance sheet is the reason this isn't an 'avoid.' Debt is negligible against $143M of equity and $57.5M of cash (~$4.29/share, ~28% of the market cap), current assets ($103M) dwarf current liabilities ($21.9M), and management is buying back stock ($9.48M in FY2025, 219,660 shares in November at $9.89 with $25M still authorized). That cushion, plus positive OCF against modest $6.83M capex, means the company can fund itself and its $25.8M R&D program without stress while it works on a turnaround.